Key statistics dashboard for Nuvation Bio Inc. (NUVB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6.
Stock Data
| Price | $5.78 |
| Market Cap | $2.0B |
| Beta | 1.61 |
| Exchange | NYSE |
| Country | US |
Valuation Multiples
| P/E Ratio | -13.36 |
| Price / Book | 7.98 |
| P/S | 11.86 |
| P/FCF | -24.36 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 93.94% |
| EBIT Margin | -76.04% |
| EBITDA Margin | -74.77% |
| Operating Margin | -81.00% |
| Net Margin | -88.19% |
Financial Health
| Current Ratio | 8.37 |
| Quick Ratio | 8.14 |
| Cash Ratio | 2.98 |
| Debt / Equity | 0.99 |
| Debt / Assets | 33.87% |
| Interest Coverage | -5.16 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.64 |
Per-Share Data
| Revenue per share | 0.49 |
| Book Value per share | 0.73 |
| Cash per share | 1.90 |
| FCF per share | -0.24 |
| Tangible Book Value per share | 0.70 |
| Dividend per share | 0.00 |
Related companies: ABCL · AUPH · CLDX · EWTX · GPCR · JANX · OCUL
Explore sector: Healthcare · Biotechnology
More sections of NUVB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks